



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 14th September, 2017

**To,
National Stock Exchange of India Limited,
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400051**

Sub: - Outcome of Board Meeting held on 14th September, 2017

Dear Sir,

A meeting of the Board of Directors of the company was held on Thursday, the 14th day of September, 2017 at 11.30 a.m. at the Corporate Office of the Company at Indore and concluded at 02.30 p.m. The Board *inter-alia* considered and approved the Unaudited Financial Results (both Standalone and Consolidated) of the company for the first quarter of the financial year 2017-18 ended on 30th June, 2017.

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith, the Unaudited Financial Results (Standalone and Consolidated basis) as on 30th June, 2017 of the Company along with the Limited Review Report given by the Statutory Auditors of the Company on the Unaudited Financial Results for the quarter ended on 30th June, 2017.

This is for the information of the exchange and members thereof.

You are requested to take the same on record.

**Thanking You
For Parenteral Drugs (India) Limited**

Anadiyana
Company Secretary





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017

Sr. No.	Particulars	(Rs in Lakh)	
		Quarter Ended 30-06-2017 (Unaudited)	Quarter Ended 30-06-2016 (Unaudited) (Ref. note 4 below)
I	(a) Revenue From Operation (Gross)	1111.11	1558.42
II	(b) Other Operating Income	63.69	2.08
III	Total Income (I+II)	1174.80	1560.50
IV	Expenditure		
	Cost of Material Consumed	107.45	525.49
	Purchase of Stock In Trade	84.67	238.62
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	23.06	124.02
	Employee Benefit Expenses	324.07	336.20
	Finance costs	2021.43	1767.97
	Depreciation and Amortisation Expenses	452.68	451.60
	Other Expenditure	856.93	845.64
	Total Expenses (IV)	3870.29	4289.54
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(2,695.49)	(2,729.04)
VI	Exceptional items	-	-
VII	Profit / (Loss) before Tax (V-VI)	(2,695.49)	(2,729.04)
VIII	Tax Expenses		
	(1) Current Tax	-	-
	(2) Deferred Tax	(554.31)	(424.70)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(2,141.18)	(2,304.34)
X	Net Profit / (Loss) for the period from discontinuing operations	-	-
XI	Tax expense of discontinuing operations	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-
XIII	Profit/(loss) for the period (IX+XII)	(2,141.18)	(2,304.34)
XIV	Other Comprehensive Income		
	A (i) Item that will not be reclassified to Profit or loss	(0.44)	(14.56)
	(ii) Income tax relation to Item that will not be reclassified to Profit or loss	-	-
	B (i) Item that will be reclassified to Profit or loss	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-
XV	Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period)	(2,141.62)	(2,318.90)
XVI	Paid Up Equity share capital(Face value Rs.10/-each)	2,981.63	2981.63
XVII	Earnings per share (for continuing operation):		
	(a) Basic	(7.18)	(7.73)
	(b) Diluted	(7.18)	(7.73)
XVIII	Earnings per share (for discontinued operation):		
	(a) Basic	-	-
	(b) Diluted	-	-
XIX	Earnings per share (for discontinued & continuing operation):		
	(a) Basic	(7.18)	(7.73)
	(b) Diluted	(7.18)	(7.73)



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- 1 The above results were reviewed by the audit committee at their meeting held on 13-09-2017 and thereafter approved by Board of Directors at their meeting held on 14-09-2017 respectively.
- 2 The statutory auditors of the company have carried out limited review of the aforesaid results.
- 3 The standalone financial results for the quarter ended June 30, 2017 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016.
The Ind AS complaint corresponding figures for the previous quarter have not been subjected to review. However, the Company's management has exercised due diligence to ensure that such financial results provided a true and fair view of its affairs.
- 4 Reconciliation of the net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:-

Description	Quarter ended 30.06.2016 Rs. In lakh
Net profit as per previous GAAP (Indian GAAP)	(2266.91)
Provisions for receivable on Expected credit loss model	58.43
Fair valuation on account of Preference shares issued	(91.35)
Deferred tax impact on above	(18.05)
Others	13.54
Net Profit as per Ind AS	(2304.34)
Other comprehensive income (net of tax expenses)	(14.56)
Total comprehensive income	(2318.90)

- 5 At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- 6 The previous period figures have been regrouped/rearranged wherever found necessary.
- 7 The Standalone financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Place: Indore
Date: 14th September 2017



Vinod Kumar Gupta
Managing Director
DIN 00039145

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F



www.jas-anz.org/register

T.N. UNNI & Co.
Chartered Accountants

402. Alankar Point,
4-A. Rajgarh Kothi,
Geeta Bhawan Square,
A.B.Road,
Indore- 452001

Standalone Limited Review Report

Limited Review Report to
The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** for the quarter ended **30th June, 2017** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *"Review of Interim Financial Information performed by the Independent auditor of the entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. IND AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: **INDORE**

Date: **14 SEP 2017**

For T.N. UNNI & Co.
Chartered Accountants



T.N. Unni
(Partner)
M. No. 14520
F.R.N. 004890C



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017

Sr. No.	Particulars	Quarter Ended 30-06-2017 (Unaudited)	Quarter Ended 30-06-2016 (Unaudited) (Ref. note 5 below)
I	(a) Revenue From Operation		
II	(b) Other Income	6244.18	7760.89
III	Total Income (I+II)	71.29	5.41
IV	Expenditure	6315.47	7766.30
	Cost of Material Consumed		
	Purchase of Stock In Trade	2351.71	2719.87
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	2355.79	2123.41
	Employee Benefit Expenses	175.80	534.08
	Finance costs	440.98	470.19
	Depreciation and Amortisation Expenses	2307.80	2071.14
	Other Expenditure	602.40	594.75
	Total Expenses (IV)	1785.39	2161.41
V	Profit / (Loss) before exceptional items and Tax (I-IV)	10019.88	10674.85
VI	Exceptional items	(3,704.41)	(2,908.55)
VII	Profit / (Loss) before Tax (V-VI)	-	-
VIII	Tax Expenses	(3,704.41)	(2,908.55)
	(1) Current Tax		
	(2) Deferred Tax		
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(527.24)	(385.40)
X	Net Profit / (Loss) for the period from discontinuing operations	(3,177.17)	(2,523.15)
XI	Tax expense of discontinuing operations	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-
XIII	Profit/(loss) for the period (IX+XII)	-	-
XIV	Other Comprehensive Income	(3,177.17)	(2,523.15)
	A (i) Item that will not be reclassified to Profit or loss		
	(ii) Income tax relation to Item that will not be reclassified to Profit or loss	(0.44)	(14.56)
	B (i) Item that will be reclassified to Profit or loss	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-
XV	Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period)	-	-
XVI	Paid Up Equity share capital(Face value Rs.10/-each)	(3,177.61)	(2,537.71)
XVII	Earnings per share (for continuing operation) :	2,981.63	2981.63
	(a) Basic		
	(b) Diluted	(10.66)	(8.46)
XVIII	Earnings per share (for discontinued operation) :	(10.66)	(8.46)
	(a) Basic		
	(b) Diluted	-	-
XIX	Earnings per share (for discontinued & continuing operation) :	-	-
	(a) Basic		
	(b) Diluted	(10.66)	(8.46)
		(10.66)	(8.46)



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- 1 The above results were reviewed by the audit committee at their meeting held on 13-09-2017 and thereafter approved by Board of Directors at their meeting held on 14-09-2017 respectively.
- 2 The statutory auditors of the company have carried out limited review of the aforesaid results.
- 3 Additional information on standalone financial results are given below:

Particulars	Rs. In Lakh	
	Quarter	Quarter
	Ended 30-06-2017	Ended 30-06-
	(Unaudited)	(Unaudited)
Total Income from operations	1,174.80	1,560.50
Profit/Loss before tax	(2,695.49)	(2,729.04)
Profit/Loss after tax	(2,141.18)	(2,318.90)

- 4 The Consolidated financial results for the quarter ended June 30, 2017 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016.
The Ind AS compliant corresponding figures for the previous quarter have not been subjected to review. However, the Company's management has exercised due diligence to ensure that such financial results provided a true and fair view of its affairs.
- 5 Reconciliation of the net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:-

Description	Quarter ended 30.06.2016 Rs. In lakh
Net profit as per previous GAAP (Indian GAAP)	(2431.41)
Provisions for receivable on Expected credit loss model	52.69
Fair valuation on account of Preference shares issued	(141.69)
Deferred tax impact on above	(16.28)
Others	13.54
Net Profit as per Ind AS	(2523.15)
Other comprehensive income (net of tax expenses)	(14.56)
Total comprehensive income	(2537.71)

- 6 At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- 7 The previous period figures have been regrouped/rearranged wherever found necessary.
- 8 The Consolidated financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Vinod Kumar Gupta
Managing Director
DIN 00039145

Place: Indore
Date: 14th September 2017



Corp. Office: Shree Ganesh Chambers, A.B. Road, Naviakhra Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register

Consolidated Limited Review Report

Limited Review Report to

The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** and its subsidiaries for the quarter ended **30th June, 2017** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *"Review of Interim Financial Information performed by the Independent auditor of the entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The financial results and other financial information of the subsidiaries have not been subjected to review and have been presented based on the financial information compiled by the company.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. IND AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: **INDORE**

Date: **14 SEP 2017**

For T.N. UNNI & Co.
Chartered Accountants




T.N. Unni
(Partner)
M. No. 14520
F.R.N. 004890C